Erratum: Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma (Blood Advances (2018) 2:16 (2039-2051) DOI: 10.1182/bloodadvances.201801604)

On page 2049, under "Authorship," the contribution paragraph should read, "Y.L.W. formed the hypothesis and directed the project; J.L., L.L.Z., W.W., H.G., M.S., G.V., S.H., H.Z., P.L., A.G., and N.G. developed the assays, designed and performed the experiments, solved technical problems, and analyzed the data; M.A. participated in IHC review and data presentation; L.L.Z., M.S., G.V., and M.L.W. contributed useful patient materials and patient pathological and treatment information; L.L.Z. and M.L.W. designed and performed the PDX study; Y.L. and J.A. performed bioinformatics analyses on the RNA-Seq data; J.L. L.L.Z., P.L., and J.A. participated in the manuscript writing; and Y.L.W. directed and coordinated the project, designed the experiments, analyzed the data, and wrote the manuscript." The errors have been corrected in the published article.